PharmaNews.eu - Dynamic European Pharmaceutical News Engine

PharmaNews.eu, an advanced web based news project targeting the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European Industry and Research pharmaceutical achievements with additional focus on the European Commission (EC) and European Medicines Agency (EMEA) news.

Many pharmaceutical companies and research organizations are experiencing continual gaps in disseminating their news. Ruslan David, owner of the PharmaNews.eu, reported: "News dissemination is a practical necessity for many existing pharmaceutical businesses and research organisations. On other side, pharmaceutical domain is requiring up-to-date and accurate information."

He added, "PharmaNews.eu is an ambitious project focused on the European pharmaceutical industry, research and EC/ EMEA achievements. It has been designed to serve as an advanced source for the European pharmaceutical news, and it will be continuously open for our readers’ contributions, comments and suggestions - a real Pharma (Web) 2.0 approach."

At this stage, PharmaNews.eu project contains Industry News from a (growing) group of the leading pharmaceutical companies, Research and Development News articles, Conferences and Events News, EMEA News, and EC Pharmaceuticals News.

All interested Internet users are invited to explore the PharmaNews.eu project where you are very welcome to register free of charge for regular updates and news alerts.

For further information, please visit:
http://www.pharmanews.eu

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...